The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

On April 2, 2025, Cingulate completed its Pre-NDA meeting with the FDA to discuss the submission of an NDA for CTx-1301, its ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for oncology and liver diseases, announced ...

Because price and margin headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.

Company announcement - No. 11 / 2025 Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, strengthening of organizational capabi ...

Possibly the most common science experiment from our school days – the egg drop challenge – now has found a place in the ...